Literature DB >> 7851549

Liver resection for colorectal liver metastases.

S Scott1, N Carty, L Anderson, I Taylor.   

Abstract

The management of patients with colorectal liver metastases is still controversial. Recent evidence suggests benefit for resection of localized metastases within a single lobe of the liver. A series of 49 patients undergoing liver resection for localized liver metastases is presented. Resection involved right hepatectomy (23), left hepatectomy (8) and segmental excision (18). The median age was 62 (range 40-77). Patients have been followed for a period of up to seven years. The overall median survival was 24 months. The actuarial 3-year survival was 57.9%. There was no significant correlation of survival with the degree of differentiation or Dukes staging of the primary tumour. This series adds further weight to the evidence supporting resection in selected patients with colorectal liver metastases.

Entities:  

Mesh:

Year:  1995        PMID: 7851549     DOI: 10.1016/s0748-7983(05)80064-2

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

Review 1.  Colorectal cancer and the liver.

Authors:  I Taylor
Journal:  Ann R Coll Surg Engl       Date:  1997-09       Impact factor: 1.891

2.  [Resection of liver metastases of colorectal tumors. A uni- and multivariate analysis of prognostic factors].

Authors:  J K Seifert; T Junginger
Journal:  Langenbecks Arch Chir       Date:  1996

3.  Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.

Authors:  S M Strasberg; F Dehdashti; B A Siegel; J A Drebin; D Linehan
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

4.  Pre-hepatectomy prognostic staging to determine treatment strategy for colorectal cancer metastases to the liver.

Authors:  Kuniya Tanaka; Hiroshi Shimada; Yoshirou Fujii; Itaru Endo; Hitoshi Sekido; Shinji Togo; Hideyuki Ike
Journal:  Langenbecks Arch Surg       Date:  2004-07-03       Impact factor: 3.445

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.